Diplomat Extends Oncology Campaign to Honor Patients
FLINT, Mich. – Sept. 6, 2016 – The nation’s largest independent specialty pharmacy continues campaign to recognize oncology patients and highlight victories, both big and small.
Diplomat Pharmacy, Inc. (NYSE: DPLO) is extending its campaign to increase awareness of Diplomat in the oncology market and to honor patients who suffer from cancer, with a focus this month on multiple myeloma.
To learn more about Diplomat’s oncology program, click here.
Cancer treatments can be complex, and patients need coordinated care to guide them through the process. Diplomat’s Oncology Center of Excellence connects the entire health care team, providing expertise and personal support throughout the patient’s journey. Physicians, nurses, pharmacists, and care staff alike—we’re all in it for the patient.
“Diplomat works to create trust between the company and our patients,” said Diplomat CEO and Chairman Phil Hagerman. “Many of our team members have experienced cancer in some way in their life, whether through a family member, friend, or personally. They know how to truly care for our patients because they have experienced it, too.”
According to the National Cancer Institute, about 1,685,000 new cases of cancer will be diagnosed in the United States in 2016. According to the World Health Organization, the number of new cases is expected to rise by about 70 percent over the next two years.
“Diplomat’s oncology team of pharmacists, nurses, and care coordinators work hard every day to help you succeed. Whether your success involves remembering to take your pills or keeping side effects at bay so you can get back to what matters most,” said Kelly Procailo, PharmD, BCOP, clinical oncology senior manager at Diplomat.
Cancer is becoming more and more prevalent, and every prescription represents a life. Join our oncology campaign and get the word out by sharing our stories and blog posts on social media using the hashtag #CancerTaughtMe.
To learn more about Diplomat, visit diplomat.is.
This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements give current expectations or forecasts of future events or our future financial or operating performance. The forward-looking statements contained in this press release are based on management’s good-faith belief and reasonable judgment based on current information. These statements are qualified by important risks and uncertainties, many of which are beyond our control, that could cause our actual results to differ materially from those forecasted or indicated by such forward-looking statements. For a discussion of such risks and uncertainties, you should review Diplomat’s filings with the Securities and Exchange Commission, including “Risk Factors” in Diplomat’s Annual Report on Form 10-K for the year ended December 31, 2015 and in subsequent reports filed with or furnished to the Securities and Exchange Commission. Except as may be required by any applicable laws, Diplomat assumes no obligation to publicly update such forward-looking statements, which are made as of the date hereof or the earlier date specified herein, whether as a result of new information, future developments or otherwise.
Diplomat (NYSE: DPLO) serves patients and physicians in all 50 states. Headquartered in Flint, Michigan, the company focuses on medication management programs for people with complex chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialized infusion therapy and many other serious or long-term conditions. Diplomat opened its doors in 1975 as a neighborhood pharmacy with one essential tenet: “Take good care of patients and the rest falls into place.” Today, that tradition continues—always focused on improving patient care and clinical adherence. For more information, visit diplomat.is.
Kali Lucas, Public Relations Coordinator
810.768.9580 | firstname.lastname@example.org
@PharmacDailyRT @PharmacDaily: @DiplomatRx to distribute Puma Biotechnology’s new cancer drug $DPLO https://t.co/gl0v6WURVV5 days ago
@DiplomatRxNerlynx (neratinib) tablets for HER2+ Breast Cancer in the Extended Adjuvant Setting https://t.co/vi3ACWhbfe5 days ago
@AJPB_JournalRT @AJPB_Journal: Be sure to check out our Insights page featuring videos of Cheryl Allen from @DiplomatRx discussing #RA https://t.co/qxZc…2 weeks ago
@DiplomatRxWe're with @340BCoalition this week in Washington D.C.! Come say hello.3 weeks ago
@SpecialtyPTimesRT @SpecialtyPTimes: Rheumatoid Arthritis Treatment Guidelines https://t.co/sEhe74UozC #rheumatoidarthritis @DiplomatRx3 weeks ago